Skip to Main Content

In the pharmaceutical world, price hikes have been the gifts that keep on giving because the hefty cumulative effects of rising price tags greatly help year-over-year revenue growth. But a new analysis suggests the trend will slow considerably as drug makers face political pressure over pricing practices.

To wit, the compounded effect of rising prices contributed, on average, 5 percent in revenue growth annually over the last five years. Although total revenue growth slowed over the past year to around 1 percent, without price increases, the sales growth would have declined by a notable 6 percent, according to Leerink analyst Geoffrey Porges, who analyzed data for 17 large drug makers.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Further confirmation of how dependent pharma has become on price increases — rather than new-therapy launches and/or market expansion for existing therapies — as their main engine of “sales growth.” I’ve often observed that this is rather like driving an out-of-gas car by repeatedly engaging the starter motor while in gear. For a while, it will create forward (if somewhat lurching) motion, but ultimately it will burn out the motor.

  • Xarelto pharmaceutical needs stopped and recalled due to there bleeding problem And J&j needs to settle out of court settlement agreement for the people’s pain and suffering from severe bleeding due to this medication

Comments are closed.